Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

PHASE4RecruitingINTERVENTIONAL
Enrollment

5,800

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

March 30, 2029

Conditions
SepsisSeptic Shock
Interventions
DRUG

Meropenem

For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion

DRUG

Piperacillin/Tazobactam

Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion

Trial Locations (2)

2100

NOT_YET_RECRUITING

Rigshospitalet, Copenhagen

Unknown

RECRUITING

Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Scandinavian Critical Care Trials Group

OTHER